In-vivo NMDA receptor density as assessed via PET during recovery from NMDA receptor encephalitis

Marian Galovic MD PhD\(^1\), Adam Al-Diwani MA BMBCh MRCP MRCPsych DPhil\(^2\), Umesh Vivekananda MD PhD\(^3\), Prof Matthew C Walker FRCP PhD\(^3\), Prof Sarosh R Irani FRCP DPhil\(^2\), Prof Matthias J Koepp MD PhD\(^*\)\(^3\) for the NEST investigators

1. Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland
2. Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
3. Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

Manuscript word count: 687
Date of revision: August 30th, 2022

* Corresponding author:
  Prof. Matthias Koepp
  UCL Institute of Neurology
  Queen Square
  London WC1N 3BG
  Tel: +44 1494 601344
  Fax: +44 1494 875666
  m.koepp@ucl.ac.uk

Full list of NEST Investigators consortium authors

Prof Franklin I Aigbirhio DPhil\(^1\), Gareth Ambler PhD\(^2\), Prof Erik Årstad PhD\(^3\), Anna Barnes PhD\(^4\), Ilaria Boscolo Galazzo PhD\(^5\), Roberto Canales PhD\(^6\), Sarah Chetcuti FFICM FRCA\(^6\), Jonathan P Coles PhD\(^6\), Bianca De Blasi PhD\(^7\), John C Dickson PhD\(^4\), John S Duncan FRCP\(^8\), Simon Eaglestone PhD\(^9\), Evan Edmond MA BMBCh MRCP\(^10\), Kjell Erlandsson BSc PhD\(^1\), Martin Fisher PhD\(^1\), Tim D Fryer BSc MSc PhD\(^1\), Thibault Gandron PhD\(^1\), Prof Ashley Groves MD\(^4\), Prof Alexander Hammers MD PhD\(^11\), Abigail Hancock-Scott\(^1\), Young T Hong PhD\(^1\), Brian Hutton PhD\(^2\), Ilijas Jelcic MD\(^12\), Roido Manavaki PhD\(^13\), Colm J McGinnity MD PhD\(^11\), Lindsay McMurray MSc PhD\(^6\), Sarah McQuaid PhD\(^4\), Alaleh Rashidnasab PhD\(^4\), Joseph J Russell PhD\(^1\), Kerstin Sander PhD\(^4\), Hasan Sari PhD\(^4\), Selena Sephton PhD\(^4\), Daichi Sone MD PhD\(^8\), Charlotte J Stagg MRCP DPhil\(^10\), Prof Kris Thielemans PhD\(^4\), Benjamin A Thomas PhD\(^4\), Francisco Torrealdea PhD\(^7\)

1. Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
2. Department of Statistical Science, University College London, London, UK
3. Centre for Radiopharmaceutical Chemistry, University College London, London, UK
4. Institute of Nuclear Medicine, University College London Hospitals, London, UK
5. Department of Computer Science, University of Verona, Verona, Italy
6. Division of Anaesthesia, Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
7. Department of Medical Physics and Bioengineering, University College London, London, UK
8. Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK
10. Physiological Neuroimaging Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
11. King’s College London and Guy’s and St Thomas’ PET Centre, Division of Imaging Sciences & Biomedical Engineering, King’s College London, London, UK
12. Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland
13. Department of Radiology, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
N-methyl-d-aspartate receptor (NMDAR)-autoantibodies are amongst the commonest causes of autoimmune encephalitis.\(^1\) *In vitro* and animal studies indicate that NMDAR internalisation is a major mechanism underlying NMDAR-antibody encephalitis.\(^2\) However, direct support for this in humans is limited to a reduction of NMDAR staining in the *post mortem* hippocampi at autopsy.\(^2, 3\)

**Methods**

We performed a cross-sectional resting-state positron emission tomography (PET) study of NMDARs *in-vivo* using the radioligand \([^{18}F]GE-179,\) currently only available for research purposes, that binds within the ion channel of the open, i.e. activated, NMDAR. We included five patients during recovery from definite NMDAR-antibody encephalitis\(^1\) (see Online Supplement for clinical characteristics) and 29 healthy volunteers who (i) could tolerate a 70-minute PET-MR scan, and (ii) took no medications which interfere with NMDARs. NMDAR-antibody encephalitis cases #1-4 had persistent GluN1-autoantibodies in serum as a marker of recent disease activity, mild symptoms, were scanned 2–8 months after hospital discharge, and were classified as persistently “seropositive”. Case #5 had undetectable serum GluN1-antibodies, was scanned 16 months after discharge from hospital and was classified as “seroreverted”. The study was reviewed and approved by the local ethical committees and all participants gave written informed consent.

We pre-processed the data as previously described\(^4\) and used \([^{18}F]GE-179\) total volume of distribution (\(V_T\)) to quantify open, activated NMDAR density. We assessed grey matter atrophy using MRI-based voxel-based morphometry and compared regional and voxel-wise data using the general linear model adjusting for age, sex, and site. We reported voxel-wise p-values <0.05 on a cluster-level corrected for multiple comparisons (\(p_{FWE}\)). We followed the STROBE reporting guideline.
Results

Seropositive cases #1-4 had lower grey matter $V_T$ (estimated marginal mean 6.2, 95% confidence interval [CI] 4.4–8.0) in comparison to both healthy volunteers (8.8, 95% CI 8.1–9.4, F=6.5, p=0.02) and the seroreverted case #5 (9.7, Fig. 1). Voxel-based analysis showed reduced $V_T$ in seropositive cases within bilateral anterior temporal lobes (left, $T=4.5, p_{FWE}=0.02$; right, $T=4.9, p_{FWE}=0.05$) and a large cluster involving bilateral superior parietal lobes, paracentral lobules, left posterior cingulate gyrus, and left precuneus ($T=5.8, p_{FWE}<0.001$). Volume of interest analyses corroborated regional $V_T$ reductions in seropositive cases in the temporal (34% reduction, $F=8.3, p=0.008$) and parietal (31% reduction, $F=7.3, p=0.01$) lobes and the mesial temporal region (40% reduction, $F=8.9, p=0.006$).

There were non-significant trends towards lower grey matter $V_T$ with higher serum GluN1 immunoglobulin G levels and shorter time from hospital discharge and from episode onset. Grey matter $V_T$ did not correlate with cognition (ACE-III questionnaire), at the time of scanning nor symptom severity at discharge (CASE score), but there was little variability between patients in these data.

There was no overlap between areas of decreased grey matter volume in the cerebellar hemispheres and regions with significantly reduced $V_T$.

Discussion

We report a large (mean 30%) regional reduction in the density of open, active NMDA receptors, most prominently in the anterior temporal and superior parietal cortices, in a small series of patients with persisting serum GluN1-autoantibodies during recovery from NMDAR-antibody encephalitis. The patients had only mild cognitive symptoms, pointing to the considerable compensatory capacity of the human brain. In contrast, a clinically
completely recovered, now seroreverted, patient had slightly elevated NMDA receptor density, which points towards normalisation or “rebound” of NMDAR function.

NMDAR hypofunction has also been observed, albeit not to such a marked degree, in patients with depression, or with first episode psychosis and correlating with psychotic and depressive symptoms. Our results are not explained by brain atrophy or brain perfusion. The potential of [18F]GE-179 PET as a clinical biomarker for NMDAR-antibody encephalitis severity and recovery should be evaluated by future studies.

Limitations include a small sample size, lack of intrathecal GluN1-autoantibody titres on scanning day, a different age and sex distribution of healthy volunteers and patients, lack of detailed cognitive testing, and lack of a comparison group with other inflammatory or encephalopathic central nervous system diseases. The findings may be more prominent in the acute phase than during disease recovery but there are logistical barriers to scanning severely affected cases. Nevertheless, our in-vivo human study supports the hypothesis of NMDA receptor internalisation and indicates the involvement of large cortical areas beyond the limbic system.
Funding

This work has been funded by an MRC PET Neuroscience programme grant (Training and Novel Probes Programme in PET Neurochemistry – MR/K02308X/1) and by an MRC Developmental Pathway Funding Scheme grant (MR/L013215/1).

Conflicts of interest of named authors

MG reports fees from Advisis, Arvelle, Bial, Eisai, Nestlé Health Science, and UCB outside the submitted work. SRI is a coapplicant and receives royalties on patent application WO/210/046716 (U.K. patent no., PCT/GB2009/051441) entitled 'Neurological Autoimmune Disorders' (licensed for the development of assays for LGI1 and other VGKC-complex antibodies) and ‘Diagnostic Strategy to improve specificity of CASPR2 antibody detection. (Ref. JA94536P.GBA; PCT/G82019 /051257). SRI has received honoraria/consultancy/research support from UCB, Immunovant, MedImmum, Janssen, ADC therapeutics, CSL Behring, and ONO Pharma. MCW reports a grant from Vitaflo and personal fees from UCB Pharma, Eisai, Sage and Marinus outside the submitted work.

Acknowledgements of named authors

The authors thank the staff at GE Healthcare, in particular William Trigg, Sajinder Kaur Luthra and Jo Stevens, for their help and support during this study.

This work was undertaken in part at UCL/UCLH which receives support from the NIHR University College London Hospitals Biomedical Research Centre. AH was supported by Medical Research Council Clinician Scientist Fellowship (G108/585) and MRC Clinical Sciences Centre core funding (MC_U120085812).

During the period of the study AAD was the recipient of a Wellcome Trust clinical research training fellowship (205126/Z/16/Z), the 2017 British Medical Association (BMA)
Foundation Margaret Temple grant, and supported by the National Institute for Health Research (NIHR) Oxford and NIHR Oxford Health Biomedical Research Centres. SRI was funded in whole or in part by a senior clinical fellowship from the Medical Research Council [MR/V007173/1], Wellcome Trust Fellowship [104079/Z/14/Z], BMA Research Grants-Vera Down grant (2013) and Margaret Temple (2017), Epilepsy Research UK (P1201), the Fulbright UK-US commission (MS-Society research award) and by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript (AAM) version arising from this submission. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

MK reports a UK MRC grant (Developmental Pathway Funding Scheme (MR/L013215/1)). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Contributions of named authors

Conception or design of the work: MG, AAD, SRI, MJK
Data collection: MG, AAD, UV, SRI
Data analysis and interpretation: MG, SRI, AAD, MCW
Study coordination: MJK, SRI
Drafting the article: MG, AAD, UV, SRI, MCW, MJK
Critical revision of the article: all authors

The conflicts of interest, acknowledgements and contributions of the full NEST investigators consortium are given in the online supplement.
Figures

**Figure 1:** $[^{18}F]$GE-179 uptake in autoantibody “seropositive” or “seroreverted” patients with NMDAR-antibody encephalitis and healthy volunteers.

The figure shows the spatial distribution of $[^{18}F]$GE-179 total volume of distribution ($V_T$) on brain slices and surface projections. **Panel A** shows mean uptake in healthy volunteers (HV, n=29, mean age 41 ± 13 years, 8 [28%] female). **Panel B** displays individual $V_T$ distributions in persistently autoantibody “seropositive” NMDAR-antibody encephalitis cases (n=4, mean age 28 ± 6 years, all female) that were scanned 2-8 months after discharge and had elevated serum GluN1-autoantibodies (1:160 – 1:320). **Panel C** displays one “seroreverted” NMDAR-antibody encephalitis case (age-range 25-30 years, female) scanned 16 months after discharge with undetectable GluN1-autoantibodies on the day of scanning.
References


NEST Investigators consortium

Full author contributions
Conception or design of the work: MG, AAD, SRI, MJK
Data collection: AH, MG, CJM, SRI, AAD, JPC, KS, EÅ, UV, FIA, TDF, YTH
Data analysis and interpretation: MG, SRI, AAD, KS, EÅ, FT, CJS, AB, KE, BAT, KT, MCW
Study coordination: MJK, SRI, CJM, AH, JPC
Drafting the article: MG, AAD, UV, SRI, MCW, MJK
Critical revision of the article: all authors

Full conflicts of interest
MG reports fees from Advisis, Arvelle, Bial, Eisai, Nestlé Health Science, and UCB outside the submitted work. IJ has received honoraria/consultancy/research support from Biogen Idec, Merck, Neutray, and Sanofi Genzyme, all outside the submitted work. CJM has received fees from GE Healthcare Ltd but neither he nor any of his family have ever been employed by the organisation; nor does he or any of his family have holdings or a financial stake in GE Healthcare Ltd. SRI is a coapplicant and receives royalties on patent application WO/210/046716 (U.K. patent no., PCT/GB2009/051441) entitled 'Neurological Autoimmune Disorders' (licensed for the development of assays for LGI1 and other VGKC-complex antibodies) and 'Diagnostic Strategy to improve specificity of CASPR2 antibody detection. (Ref. JA94536P.GBA; PCT/G82019/051257). SRI has received honoraria/consultancy/research support from UCB, Immunovant, MedImmum, ADC therapeutics, CSL Behring, and ONO Pharma. KS is funded by Mallinckrodt Pharmaceuticals. EÅ collaborates with Cerveau Technologies on unrelated studies. MCW reports a grant from Vitafo and personal fees from UCB Pharma, Eisai, Sage and Marinus outside the submitted work.

Full acknowledgements
The authors thank the staff at GE Healthcare, in particular William Trigg, Sajinder Kaur Luthra and Jo Stevens, for their help and support during this study. This work was undertaken in part at UCL/UCLH which receives support from the NIHR University College London Hospitals Biomedical Research Centre. AH was supported by Medical Research Council Clinician Scientist Fellowship (G108/585) and MRC Clinical Sciences Centre core funding (MC_U120085812). Authors affiliated with King’s College London acknowledge support by the UK Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust, and by the Wellcome EPSRC Centre for Medical Engineering at King’s College London (WT 203148/Z/16/Z). During the period of the study AAD was the recipient of a Wellcome Trust clinical research training fellowship (205126/Z/16/Z), the 2017 British Medical Association (BMA) Foundation Margaret Temple grant, and supported by the National Institute for Health Research (NIHR) Oxford and NIHR Oxford Health Biomedical Research Centres. CM was supported by the Medical Research Council (MR/N013042/1) and subsequently by the Wellcome Trust/Engineering and Physical Sciences Research Council (EPSRC) Centre for Medical Engineering (WT 203148/Z/16/Z) and the Engineering and Physical Sciences...
Research Council Centre for Doctoral Training in Medical Imaging (EP/L015226/1). JPC & FIA report a UK Medical Research Council (MRC) grant (MRC Industry Collaboration Agreement (MR/K02308X/1)), and MK, JPC & FIA report a UK MRC grant (Developmental Pathway Funding Scheme (MR/L013215/1)). JPC reports a British Journal of Anaesthesia/Royal College of Anaesthetists grant from the National Institute of Academic Anaesthesia. JPC is supported by the Cambridge NIHR Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.